Blood cancers are a major cause of cancer-related deaths in Australia. Our research focuses on how malignant and immune cells interact within the bone marrow microenvironment, with the aim to develop more precise therapeutic strategies for conditions such as myelodysplastic syndromes (MDS), multiple myeloma, and related haematological malignancies.
Areas of interest
Research group
Biography
Associate Professor George Grigoriadis MBBS, BSc, BMedSci, PhD, FRACP, FRCPA is a Clinical and Laboratory Haematologist at The Alfred and Bass Coast Health, and an Associate Professor in the Department of Medicine at Monash University. He leads a translational haematology research program at the Centre for Cancer Research at the Hudson Institute of Medical Research focused on improving the diagnosis, risk stratification, and treatment of myelodysplastic syndromes (MDS), multiple myeloma, and related haematological disorders.
His research integrates clinical haematology, genomics, and experimental biology to understand how genetic and microenvironmental factors influence disease initiation, progression, and therapeutic response. A major area of focus is the role of inflammatory signalling and immune dysregulation in myeloid malignancies, with the aim of identifying biomarkers and therapeutic targets that can improve patient outcomes.
Associate Professor Grigoriadis was awarded a prestigious Victorian Cancer Agency Clinical Research Fellowship (2014–2018), through which he investigated stage-specific inflammation and immunomodulation in MDS. He has also led and contributed to genomic studies applying whole-genome and transcriptome sequencing to predict treatment response and disease progression. His work has been published in leading journals including Blood, Leukemia, Cell Death & Differentiation, and British Journal of Haematology.
Through close collaboration with clinicians and laboratory researchers, his program seeks to translate genomic and immunological discoveries into clinically actionable strategies. His research emphasises the integration of molecular profiling with clinically annotated patient cohorts to advance precision medicine approaches for individuals with haematological malignancies.
Publication highlights
